Extended-Release Niacin/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus

201212 citationsJournal Article

Authors

Harold Bays · Louisville Metabolic and Atherosclerosis Research Center

James M. McKenney · National Clinical Research

Edward A. O’Neill · Merck & Co., Inc., Rahway, NJ, USA (United States)

Andrew M. Tershakovec · Merck & Co., Inc., Rahway, NJ, USA (United States)

Abstract

Compared with placebo in patients with T2DM, ERN/LRPT shifted the lipoprotein profile toward a potentially less atherogenic pattern with reduced atherogenic LDL and IDL particle concentrations, and increased large HDL plasma particle concentrations. (ClinicalTrials.gov: NCT00485758).

Topics & Keywords

Lipoproteins and Cardiovascular Health Diabetes, Cardiovascular Risks, and Lipoproteins Pharmacology and Obesity Treatment

Publication Details

Published in: Metabolic Syndrome and Related Disorders

Volume 10, Issue 4, pp. 260-266

DOI: 10.1089/met.2012.0005

Field-Weighted Citation Impact: 1.76

Command Palette

Extended-Release Niacin/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus

Authors

Abstract

Topics & Keywords

Publication Details